Stocks · News reference
Filed: 2026-10-29 AccNo: 0001356576-26-000050 Size: 461 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Indivior Pharmaceuticals reported its third-quarter 2026 financial results and confirmed that its merger with Supernus Pharmaceuticals is expected to close on November 2, 2026.
Newron Pharmaceuticals has finished patient enrollment for its Phase 3 study of evenamide, a glutamate modulator for which Supernus Pharmaceuticals holds U.S. marketing rights.
Supernus Pharmaceuticals (NASDAQ:SUPN) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time